Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$1.02
0.022%
Last update: Oct 21, 7:28 PM
$1.05
0.055%
Coherus Oncology Inc (CHRS) Stock Price, Quote, News & History
CHRSNASDAQ
| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and...
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of Coherus Oncology (NASDAQ:CHRS) through any online brokerage.
Other companies in Coherus Oncology’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Coherus Oncology has a consensus price target of $7.12.
The stock price for Coherus Oncology (NASDAQ: CHRS) is $1.05 last updated October 21, 2026 at 7:28 PM EDT.
There are no upcoming dividends for Coherus Oncology.
Coherus Oncology does not have any upcoming earnings scheduled.
There is no upcoming split for Coherus Oncology.
Coherus Oncology is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
